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Abstract 32 
Study Objectives 33 
In this systematic review and meta-analysis, we aimed to examine the relationship between 34 
obstructive sleep apnoea (OSA) and metabolic abnormalities in women with polycystic ovary 35 
syndrome (PCOS). 36 
Methods 37 
Electronic databases (Medline, Embase, Cinahl, PsycInfo, Scopus, Web of Science, Opengrey, 38 
CENTRAL), conference abstracts, and reference lists of relevant articles were searched. No 39 
restriction was applied for language or publication status.  40 
Results 41 
Six studies involving 252 participants were included. Women with PCOS and OSA had significantly 42 
higher body mass index (mean difference [MD]: 6.01 kg/m
2
, 95% Confidence Intervals [CI]: 4.69-43 
7.33), waist circumference (MD: 10.93 cm, 95% CI: 8.03-13.83), insulin resistance, systolic and 44 
diastolic blood pressure, as well as worse lipids’ profile and impaired glucose regulation compared to 45 
women with PCOS without OSA. Most studies did not adjust for weight in their between groups 46 
analysis. Total and free testosterone levels were not significantly different between the two groups. 47 
The majority of studies were found to be at high risk of selection bias; did not account for important 48 
confounders; were conducted in one country (USA); and used different methodologies to assess 49 
testosterone levels (preventing a meta-analysis for this specific outcome). 50 
Conclusions 51 
OSA is associated with obesity and worse metabolic profiles in women with PCOS. However, 52 
whether the effects of OSA are independent of obesity remain unclear. As OSA is a treatable 53 
condition, research focused on the independent effects of OSA on key clinical outcomes in women 54 
with PCOS, including fertility, psychological health, type 2 diabetes and cardiovascular risk is lacking 55 
and needed. 56 
Key words: Polycystic ovary syndrome; PCOS; Obstructive Sleep Apnoea; OSA; Hyperandrogenism; 57 
Obesity; Insulin Resistance.  58 
PROSPERO registration number: CRD42016048587. 59 
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Statement of Significance 61 
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of 62 
reproductive age. PCOS is associated with significant comorbidities. Our systematic review and 63 
meta-analysis showed that women with PCOS and obstructive sleep apnoea (OSA) are more obese 64 
and have a worse metabolic profile compared to women with PCOS without OSA. However, whether 65 
the effects of OSA are independent of obesity remain unclear. In particular, the independent effects 66 
of OSA on important clinical outcomes in women with PCOS including fertility, type 2 diabetes, 67 
psychological health, quality of life and cardiovascular disease are yet to be investigated. Future 68 
studies need to assess the impact of OSA, and its treatment, on important clinical outcomes in 69 
women with PCOS.  70 
  71 
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1. Introduction 72 
Obstructive sleep apnoea (OSA) is a common medical condition that is highly prevalent in women 73 
with polycystic ovary syndrome (PCOS) and obesity 
1
. OSA is characterised by recurrent episodes of 74 
upper airway closure, drop in oxygen levels and sleep fragmentation, with subsequent increase in 75 
sympathetic activity, insulin resistance, oxidative stress and abnormal gonadotropin releasing 76 
hormone (GnRH) secretion 
2
. The same spectrum of hormonal and metabolic abnormalities are also 77 
commonly seen in PCOS and are thought to play a role in its aetiology 
1
. This led some investigators 78 
to suggest that OSA may lead to a more severe form of PCOS in affected women 
3
.  79 
PCOS is the most prevalent endocrine disorder in women of reproductive age 
4,5
, and is associated 80 
with significant comorbidities including subfertility 
6
, impaired quality of life (QoL) 
7-9
, and increased 81 
risk of type 2 diabetes 
10
 and cardiovascular disease (CVD) 
11
.  Hence, in this study, we aimed to 82 
conduct a systematic review and meta-analysis examining the relationship between OSA and 83 
metabolic abnormalities in women with PCOS. Moreover, apart from weight loss, there are limited 84 
safe and effective treatment options available for women with PCOS and obesity 
12
. Continuous 85 
positive airway pressure (CPAP) has been shown to improve insulin resistance, reduce oxidative 86 
stress and inflammation and improve quality of life in patients with OSA 
2
; hence examining the 87 
impact of OSA in women with PCOS might allow identifying new treatment strategies. 88 
 89 
2. Objectives 90 
To examine the effect of OSA on clinical, metabolic, and psychological health in women with PCOS. 91 
 92 
3. Methods 93 
Our systematic review protocol was prospectively registered with PROSPERO: CRD42016048587 94 
(http://www.crd.york.ac.uk/PROSPERO/) and herein we report our findings according to the 95 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline 
13,14
. 96 
 97 
3.1 Selection criteria 98 
We included any human study, observational or interventional, that included two groups of women 99 
with PCOS based on the presence/absence of OSA (namely a PCOS group with OSA and a PCOS 100 
group without OSA) and reported any clinical, metabolic, or psychological outcomes/measures in 101 
these women. 102 
Only studies that used cardiorespiratory monitoring devices (polysomnography or Level III devices) 103 
for the diagnosis of OSA were included, regardless of the cut-offs used to diagnose OSA. Level III 104 
devices are acceptable methods to diagnose OSA as detailed in the latest American Academy of 105 
Sleep Medicine (AASM) guidelines 
15
. Level III devices were defined, as per AASM guidelines, as 106 
portable machines that could be used at home and record two respiratory variables (e.g., effort to 107 
breathe, airflow), oxygen saturation, and a cardiac variable (e.g., heart rate or electrocardiogram) 
15
. 108 
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Both studies published in peer-reviewed journals and conference abstracts were included. 109 
Studies in both adolescent (postmenarchal) girls and adult (premenopausal and postmenopausal) 110 
women with PCOS were included (no age limit). Articles that examined women with PCOS were 111 
included, regardless of the diagnostic criteria used for PCOS diagnosis. Women with PCOS from any 112 
ethnicity were included. 113 
 114 
3.2 Study outcomes 115 
Differences between women with PCOS and OSA compared to women with PCOS without OSA in 116 
weight, body mass index (BMI), waist circumference, waist-to-hip-ratio (WHR), IR, impaired glucose 117 
regulation, free testosterone, total testosterone, sex hormone binding globulin (SHBG), lipids profile, 118 
blood pressure, hirsutism, QoL, psychological health, menstrual period regularity, previous diagnosis 119 
of subfertility, T2DM and CVD prevalence. 120 
 121 
3.3 Search strategy 122 
The initial search for relevant articles was conducted on the 11
th
 of April 2016 and was updated on 123 
the 7
th
 of February 2017. The search was not restricted by language or publication status. We 124 
searched the following electronic databases: Medline (Ebsco), Embase (Ovid), Cinahl (Ebsco), 125 
PsycInfo (ProQuest), Scopus, Web of Science, Opengrey, and Cochrane Central Register of Controlled 126 
Trials (CENTRAL). In addition, we also searched major respiratory and endocrinology conferences for 127 
relevant abstracts. We also manually searched the references of relevant papers and review articles. 128 
The detailed search strategy for each database is provided in Appendix 1 in the online data 129 
supplement. 130 
 131 
3.4 Selection of studies 132 
The screening of the titles and abstracts was conducted independently by two authors (HK and IK) 133 
and we discarded studies that were not relevant and did not meet the systematic review selection 134 
criteria. Full text articles of all potentially relevant articles were reviewed. Any disagreements 135 
between the two authors were resolved by consensus and discussion with a third author (OU), if 136 
necessary. 137 
 138 
3.6 Data extraction and management 139 
Data from included studies were extracted by two authors (HK and IK) independently. Where studies 140 
had multiple publications, the main study report was used as the reference and additional details 141 
supplied from secondary papers. Review authors corresponded with study investigators in order to 142 
resolve any data queries, as required. For each study that met the selection criteria, details were 143 
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extracted on study design, study population characteristics, and prevalence estimates. Any 144 
disagreements were resolved by consensus and discussion with a third author (OU), if necessary. 145 
 146 
3.7 Risk of bias 147 
The risk of bias of included studies was assessed by two authors (HK and IK) independently and any 148 
disagreements were resolved by consensus and discussion with a third author (OU), if necessary. The 149 
following domains of risk of bias were assessed “selection bias (sample population), selection bias 150 
(confounding variables), performance bias (measurement of exposure), performance bias (analytical 151 
methods to control for bias) and other bias”, using the Risk of Bias Assessment Tool for 152 
Nonrandomised Studies (RoBANS) 
16
 to appraise the risk of bias for each included study. Each 153 
domain was classified as high risk; low risk; or unclear. 154 
 155 
3.8 Unit of analysis 156 
The following definitions were used: fertility [fecundity (number of children); needing assisted 157 
fertility; infertility (failure to achieve a clinical pregnancy after 12 months or more of regular 158 
unprotected sexual intercourse); and number of miscarriages]; IR [homeostasis model for insulin 159 
resistance (HOMA-IR)]; impaired glucose regulation [IGT: fasting plasma glucose 6.1–6.9 mmol/L;  2-160 
hour plasma glucose 7.8–11 mmol/L after a standard oral glucose tolerance test (OGTT); or 161 
haemoglobin A1C (HbA1C) 42–47 mmol/mol); T2DM [fasting plasma glucose ≥7.0 mmol/L; 2-hour 162 
plasma glucose ≥11.1 mmol/L after a standard OGTT; or HbA1C ≥48 mmol/mol] 
17,18
; period 163 
regularity (number of periods per year); blood pressure (mmHg); hirsutism (modified Ferriman-164 
Gallwey score); weight (kg); BMI (kg/m
2
); waist circumference (cm); QoL (using any validated QoL 165 
questionnaire); depression (either using questionnaires or clinical, for example taking medications 166 
for depression); anxiety (using questionnaires); and metabolic syndrome (using any internationally 167 
recognised criteria). For biochemical and hormonal measurements SI units were used and 168 
conversion to SI units was performed, if needed. Data are presented as mean ± standard deviation 169 
(SD) and conversion from 95% confidence intervals (CI) and standard error of the mean (SEM) values 170 
to SD was performed, if needed, in accordance with the Cochrane Handbook for Systematic Reviews 171 
of Interventions (http://handbook.cochrane.org/).  172 
 173 
3.9 Data synthesis 174 
The results of the studies which were found to be statistically homogeneous were pooled using the 175 
fixed-effect meta-analysis. Otherwise, we used random-effects meta-analysis. For continuous 176 
outcomes that were measured on the same scale, we combined the mean differences to calculate 177 
the (weighted) mean difference and SD. Between studies heterogeneity was assessed using Higgins’s 178 
I
2
 statistics and a value greater than 50% was considered to be indicative of moderate heterogeneity 179 
19,20
. All analyses were conducted in Stata version 14 for Windows (Stata Corp, College Station, 180 
Texas).  181 
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4. Results 182 
4.1 Search results and study characteristics 183 
A PRISMA ﬂow diagram of the search results is shown in Figure 1. The main characteristics of the six 184 
included and 22 excluded studies are summarised in Table 1 and Table S1, in the online data 185 
supplement, respectively. Of the six included studies: (i) four studies included women with obesity; 186 
one study included overweight women; and one study did not report the exact BMI values of the 187 
participants (although 22 participants were obese and 9 were lean); (ii) one study included 188 
adolescent girls, three studies included mixed populations (adolescents and adults), and two studies 189 
included adult women with PCOS (Table 1). Of note, the majority of the included studies (four out of 190 
six) were conducted in one country, namely in the USA. All studies used polysomnography to 191 
diagnose OSA. One study, Nandalike et al. 2012 
21
, was a retrospective chart review study. 192 
 193 
4.2 Risk of bias of included studies 194 
The risk of bias assessment for each study is summarised in Figure 2. The selection bias due to 195 
inadequate selection of participants was high in three studies and unclear in the remaining three. 196 
The selection bias caused by inadequate confirmation and consideration of confounding variable(s) 197 
was high in all six studies. The performance bias due to inadequate measurement of exposure was 198 
low in four studies and high two studies. The detection bias due to inadequate blinding of outcome 199 
assessments was high in one study and unclear in the remaining five. The attrition bias due to 200 
inadequate handling of incomplete outcome data was low in three studies and unclear in three 201 
studies. The reporting bias due to selective reporting was low in five studies and high only in one 202 
study. 203 
 204 
4.3 Effect of OSA in women with PCOS on clinical outcomes 205 
Anthropometric measures   206 
Women with PCOS and OSA had significantly higher BMI (mean difference [MD]: 6.01 kg/m
2
, 95% CI: 207 
4.69-7.33; I
2
 = 0%; four studies; 193 participants), waist circumference (MD: 10.93 cm, 95% CI: 8.03-208 
13.83; I
2
 = 13%; two studies; 88 participants) and WHR (MD: 0.10, 95% CI: 0.03-0.17; one study; 38 209 
participants) (Figure 3). In the sub group of adolescent girls with PCOS and obesity, there was no 210 
significant difference in BMI-Z scores between girls with OSA compared to those without OSA, Figure 211 
3. None of the nine lean adolescent girls with PCOS in the study by Kenigsberg et al. had OSA 22. 212 
 213 
Blood pressure  214 
Two studies reported the blood pressure effect of OSA in women with PCOS (Figure 4). The pooled 215 
association showed that on average the systolic blood pressure was significantly higher by 10.8 216 
mmHg in women with PCOS and OSA compared to women with PCOS without OSA (95% CI: 6.21-217 
15.39; I
2
 = 0%; two studies; 78 participants). Similarly, the diastolic blood pressure was significantly 218 
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higher by 4.63 mmHg in women with PCOS and OSA than in women with PCOS without OSA (95% CI: 219 
1.06-8.21; I
2
 = 0%; two studies; 78 participants). Neither study adjusted for BMI in their analysis. 220 
While participants in the study by Nandalike et al. 
21
 had similar age, no age was reported for 221 
participants in the study by Chatterjee et al. 
23
. 222 
 223 
Hirsutism and reproductive outcomes  224 
One included study measured the Ferriman-Gallwey score as a marker of hirsutism (Figure 5) and 225 
reported that this score was higher in women with PCOS and OSA compared to those without OSA 226 
(MD: 1.82, 95% CI: 0.30-3.34; 50 participants), but this difference was not adjusted for BMI which 227 
was higher in the PCOS OSA group.  228 
None of the included studies reported outcomes relating to the regularity of menstrual periods or to 229 
fertility in women with PCOS and OSA. 230 
 231 
4.4 Effect of OSA in women with PCOS on hormonal/metabolic outcomes 232 
Sex Hormone binding globulin (SHBG)  233 
Two studies reported circulating levels of SHBG. SHBG levels tended to be lower in women with 234 
PCOS and OSA than in those without OSA, albeit this trend did not reach statistical significance when 235 
these two studies were pooled (MD: -7.73, 95% CI: -15.90-0.45, I
2
 = 67%; 90 participants) (Figure 5). 236 
 237 
Total and free testosterone plasma levels  238 
Due to the different methods and units used to measure and report testosterone plasma levels, 239 
respectively, it was not possible to combine the reported total or free testosterone results between 240 
studies. In addition, in certain studies 
24,25
 the reported testosterone levels were outside the range 241 
expected for women with PCOS. Thus, we adopted a descriptive analysis for this outcome which is 242 
presented in Table 2. As such, in each of the four studies that reported total testosterone levels, 243 
these were not significantly different between women with PCOS and OSA compared to women with 244 
PCOS without OSA. Similarly, free testosterone levels were not significantly different between these 245 
two groups in four studies reporting this outcome, whereas one study reported higher free 246 
testosterone levels in women with PCOS and OSA compared to women with PCOS without OSA 247 
(Table 2). 248 
 249 
Glucose metabolism and insulin resistance measures 250 
Women with PCOS and OSA had significantly higher: (i) fasting plasma glucose levels (MD: 0.45 251 
mmol/L, 95% CI: 0.21-0.69; I
2
 = 17%; five studies; 221 participants); (ii) 2-hour plasma glucose on 252 
OGTT (MD: 1.39 mmol/L, 95% CI: 0.67-2.11; I
2
 = 0%; two studies; 90 participants); (iii) HOMA-IR (MD: 253 
2.23, 95% CI: 1.41-3.06; I
2
 = 0%; four studies; 168 participants); and (iv) fasting plasma insulin levels 254 
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(MD: 10.03, 95% CI: 3.20-16.85; I
2
 = 78%; four studies; 183 participants) (Figure 6). Only two studies 255 
24,25
 adjusted for BMI in their between group analysis. In the study by Kenigsberg et al.
22
 there was 256 
no significant difference in insulin resistance, measured using hyperinsulinaemic euglycaemic 257 
clamps, in the subgroup analysis between girls with PCOS and obesity with and without OSA.   258 
 259 
Blood lipids  260 
Women with PCOS and OSA had significantly higher plasma levels of: (i) total cholesterol (MD: 0.74 261 
mmol/L, 95% CI: 0.30-1.18; I
2
 = 0%; two studies; 88 participants); (ii) LDL cholesterol (MD: 0.52 262 
mmol/L, 95% CI: 0.18-0.86; I
2
 = 25%; two studies; 88 participants); and (iii) triglycerides (MD: 0.35 263 
mmol/L, 95% CI: 0.18-0.52; I
2
 = 0%; three studies; 116 participants). Contrary, HDL cholesterol 264 
plasma levels were significantly lower in women with PCOS and OSA compared to those without OSA 265 
(MD: -0.26 mmol/L, 95% CI: -0.36- -0.16, I
2
 = 0%; three studies; 116 participants) (Figure 7). None of 266 
the studies adjusted for BMI in their between group data analysis. 267 
 268 
Metabolic Syndrome  269 
Women with PCOS and OSA had a significantly higher metabolic syndrome incidence rate compared 270 
to women with PCOS without OSA (rate difference = 37.2%, 95% CI: 19.3-55.1; I
2
 = 0%; two studies; 271 
78 participants) (Figure 8). 272 
 273 
4.5 Effect of OSA in women with PCOS on psychological outcomes 274 
None of the included studies reported on QoL and psychological outcomes. 275 
 276 
5. Discussion  277 
This is the first systematic review and meta-analysis to examine the association of OSA with 278 
metabolic abnormalities in women with PCOS. Our data showed that women with PCOS and OSA 279 
have more central and generalised obesity and exhibit a more severe metabolic profile compared to 280 
women with PCOS without OSA. However, the relationship between OSA and the clinical features of 281 
PCOS (such as hirsutism, and menstrual irregularities) as well as CVD, QoL and fertility outcomes 282 
remains unclear.  283 
Obesity is a major risk factor for OSA 
26
. Thus, it is not surprising that women with PCOS and OSA 284 
were more obese compared to those without OSA in our analysis. This excess adiposity potentially 285 
places these women at higher risk of T2DM and CVD, but whether this increased risk is due to excess 286 
adiposity or OSA has not been studied yet. It is worth noting that several studies suggested that 287 
women with PCOS have a higher prevalence of OSA compared to women without PCOS 
21,24,25
;  but 288 
differences in studies populations (e.g. obesity, ethnicity) or methods of participants’ recruitment 289 
(e.g. community, specialised clinics) have generally not been adequately accounted for. 290 
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The severity of hirsutism in women with PCOS and OSA was assessed only in one study using the 291 
Ferriman-Gallwey score. Although the score was higher when OSA was present, the difference 292 
between the two groups was small (MD: 1.82) and, hence, is of doubtful clinical significance. It was 293 
also not clear if the assessor was blinded to the OSA status of study participants.  294 
The majority of studies did not show a statistically significant difference in circulating total or free 295 
testosterone levels between women with PCOS and OSA compared to those without OSA. There was 296 
a trend for women with PCOS and OSA to have lower SHBG compared to women without OSA, but 297 
this did not reach statistical significance. Overall, based on the existing studies, our findings suggest 298 
that the role of hyperandrogenism in the development of OSA in women with PCOS is probably 299 
limited. Of note, this finding challenges previous presumptions that hyperandrogenism is a key 300 
factor in the increased risk of OSA in women with PCOS 
27,28
. Hyperandrogenism is thought to be an 301 
important factor in the increased prevalence of OSA in men compared to women, through 302 
mechanisms including increased upper airway collapsibility and impaired sensitivity and 303 
responsiveness of the ventilatory chemoreceptors 
29
. However, the level of hyperandrogenism in 304 
women with PCOS is much lower compared to that in men which may explain this apparent 305 
discrepancy 
1
. 306 
No study has examined the effects of OSA on fertility outcomes in women with PCOS. As PCOS is the 307 
most common cause of ovulatory dysfunction 
30
, and OSA is highly prevalent in obese women with 308 
PCOS 
1
, it is important to examine whether OSA has an impact on fertility in women with PCOS. 309 
Our meta-analysis showed that women with PCOS and OSA were more insulin resistant compared to 310 
women with PCOS without OSA. The large difference in BMI between these two groups (MD: 6.0 311 
kg/m
2
) in the included studies makes it difficult to exclude obesity as a confounding factor in this 312 
association, despite the statistical adjustment for BMI in some of these studies 
25
. However, studies 313 
in the general population also suggest an association between OSA and IR 
31-33
. This association 314 
between OSA and IR in women with PCOS is further supported by an interventional study involving 315 
19 obese women with PCOS and OSA [age (±SEM) 31.2 ±1.2 years, BMI 46.4 ±2.4 kg/m
2
] who 316 
underwent CPAP treatment for 8 weeks that resulted in significant improvement in insulin sensitivity 317 
34
. However, the reported results of this study were based on ‘per protocol’ analysis involving a small 318 
sample (n=9) without a control group. Moreover, as women with PCOS have a 4-fold higher risk of 319 
T2DM compared to weight-matched controls 
10
, and OSA is an independent risk factor for the 320 
development of T2DM in general population studies 
2,33
, it is possible that  part of this increased 321 
T2DM risk is secondary to undiagnosed OSA which was not accounted for. Well conducted, large, 322 
cohort and interventional studies are needed to assess the incidence of T2DM and the impact of 323 
CPAP therapy on insulin sensitivity and glucose metabolism in women with PCOS and OSA. 324 
Our meta-analysis also showed that women with PCOS and OSA had higher blood pressure, more 325 
atherogenic plasma lipids profile and higher incidence rates of the metabolic syndrome compared to 326 
those without OSA. While this suggests that women with PCOS and OSA represent a group of 327 
patients at higher CVD risk compared to women with PCOS without OSA, it is difficult to exclude the 328 
role of obesity in this association from the conducted studies. However, in the general population 329 
OSA has been also associated with increased risk of hypertension, CVD and mortality 
2,35
. 330 
Intermittent hypoxia, endothelial dysfunction, increased IR, sympathetic overactivity, inflammation 331 
and oxidative stress may play a role in the development of cardiometabolic comorbidities in OSA 332 
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36,37
. Notably, in the aforementioned interventional study by Tasali et al. 
34
 the 8-week CPAP 333 
treatment in women with PCOS and OSA was also associated with a reduction in diastolic blood 334 
pressure (by approximately 2.3 mmHg) and a reduction in day-time and night-time norepinephrine 335 
levels. As PCOS is associated with increased CVD risk 
11
, OSA may represent an important modifiable 336 
risk factor in the management of these patients. 337 
No study has examined the effects of OSA on psychological health, anxiety or depression in women 338 
with PCOS. As both OSA 
38-40
 and PCOS 
7-9
 are independently associated with low mood and impaired 339 
QoL, an effect for OSA on psychological health in women with PCOS is possible. Thus, targeted 340 
research is also needed in this area. 341 
Another important area for research where there is a lack of data is ethnicity and its influence on 342 
PCOS and OSA interaction. Clinical studies suggest that the prevalence and pathophysiology of OSA 343 
are influenced by ethnicity, through mechanisms including body fat distribution, craniofacial 344 
anatomy, and low arousal threshold 
41,42
. Of note, multiple aspects of PCOS metabolic and clinical 345 
features, including obesity, IR, hirsutism, T2DM risk, CVD risk markers, oligomenorrhoea, and 346 
possibly response to fertility treatment, are also influenced by ethnicity 
43,44
. Subsequently, research 347 
focused on the prevalence and impact of OSA in women with PCOS from different ethnic 348 
backgrounds is needed to help identify high risk populations and those who are affected most by the 349 
condition, and, thus, may potentially benefit more from intervention(s) to treat OSA. 350 
CPAP is an effective treatment for patients with OSA and observational studies suggest that patients 351 
who are compliant with treatment (using CPAP > 4 hours/night) not only notice improvement in 352 
night-time apnoeas and daytime sleepiness, but also in IR, oxidative stress and sympathetic 353 
overactivity 
31,34,45
. As these mechanisms may also play a role in the aetiology of PCOS 
1
, CPAP 354 
treatment in women with PCOS and OSA may have a favourable impact on the clinical 355 
manifestations of the syndrome including hypertension, increased risk of T2DM and CVD, poor 356 
psychological health, and subfertility. 357 
 358 
6. Study limitations  359 
Our systematic review has identified a small number of studies that examined the relationship 360 
between OSA and metabolic features in women with PCOS and the majority of them were found to 361 
be at high risk of selection bias; did not account for important confounding factors; were conducted 362 
in one country (i.e., in the USA); and had relatively small sample sizes. Subsequently, it is difficult to 363 
draw firm conclusions on the independent effects of OSA on metabolic outcomes in women with 364 
PCOS. Narrative synthesis, rather than meta-analysis, was performed when assessing the effects of 365 
OSA on hyperandrogenism in women with PCOS due to the different measurement methods and 366 
units reported. It was not possible to account for the severity of OSA as the majority of studies did 367 
not report AHI (Table 1); although when AHI was reported, the study population had moderate OSA.  368 
 369 
The following deviation from our original protocol should also be noted: for the included studies we 370 
accepted the study authors own definition of OSA, and PCOS, regardless of the diagnostic criteria 371 
used. However, we do not feel that including these studies have affected our results as the AHI cut-372 
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off to diagnose OSA is different in children than in adults; all the studies included have used 373 
polysomnography to diagnose OSA; and all have used the NIH or the Rotterdam criteria to diagnose 374 
PCOS (Table 1). 375 
 376 
7. Study strengths 377 
This is the first systematic review to examine the effects of OSA in women with PCOS. We have 378 
followed internationally recognised recommendations in conducting and reporting this systematic 379 
review and meta-analysis. Our literature search was broad, in terms of the number of different 380 
sources/databases searched, and it was not restricted by publication type or year, language, or study 381 
design. 382 
 383 
8. Conclusions 384 
OSA is associated with worse clinical and metabolic profiles in women with PCOS, but whether this is 385 
independent of obesity remains unclear. The link between OSA and hyperandrogenism in women 386 
with PCOS is probably small. Large, well conducted, observational and interventional studies are 387 
needed to examine the independent effect of OSA in women with PCOS. As OSA is highly prevalent 388 
and a treatable condition, research focused on OSA and important clinical outcomes in women with 389 
PCOS, including fertility, psychological health, CVD and T2DM risk, is lacking and needed. 390 
 391 
9. Abbreviations list  392 
- AASM   American Academy of Sleep Medicine 393 
- AA  African American 394 
- AHI   Apnoea/hypopnoea index 395 
- AI  Apnoea index  396 
- BMI  Body mass index 397 
- C. abstract Conference abstract 398 
- CIs  Confidence intervals 399 
- CPAP   Continuous positive airway pressure 400 
- CS  Cross-sectional study 401 
- CVD   Cardiovascular disease 402 
- GnRH   Gonadotropin releasing hormone 403 
-  h   Hour  404 
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- HbA1C   Haemoglobin A1C 405 
- HOMA-IR  Homeostatic model assessment of insulin resistance 406 
- IR   Insulin resistance 407 
- J. Article Journal article 408 
- MD   Mean difference 409 
- N  Sample size 410 
- NIH   National Institutes of Health 411 
- NR  Not reported 412 
- NS  Not significant  413 
- OGTT   Oral glucose tolerance test 414 
- OSA   Obstructive sleep apnoea 415 
- PCOS   Polycystic ovary syndrome 416 
- PRISMA  Preferred Reporting Items for Systematic Reviews and Meta-analyses 417 
- PSG   Polysomnography  418 
- QoL   Quality of life 419 
- RDI  Respiratory distress index  420 
- SD   Standard deviation 421 
- SEM   Standard error of the mean 422 
- SHBG   Sex hormone binding globulin 423 
- T2DM   Type 2 diabetes mellitus 424 
- WHR  Waist-to-hip ratio  425 
- Yr   Years 426 
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Figure 1. PRISMA flow diagram. 563 
 564 
Figure 2. Risk of bias of included studies. 565 
 566 
Figure 3. Effect of obstructive sleep apnoea (OSA) on anthropometric measures in women with 567 
polycystic ovary syndrome (PCOS) [body mass index (BMI in kg/m2) for adult women with PCOS; 568 
BMI Z-score for the sub group of adolescent girls with obesity and PCOS; waist circumference; 569 
waist-to-hip ratio (WHR); women with PCOS and OSA (PCOS OSA); women with PCOS without OSA 570 
(PCOS No OSA)]. 571 
 572 
Figure 4. Effect of obstructive sleep apnoea (OSA) on systolic and diastolic blood pressure in 573 
women with polycystic ovary syndrome (PCOS) [women with PCOS and OSA (PCOS OSA); women 574 
with PCOS without OSA (PCOS No OSA)]. 575 
 576 
Figure 5. Effect of obstructive sleep apnoea (OSA) on hirsutism (based on the modified Ferriman-577 
Gallwey score) and sex hormone binding globulin in women with polycystic ovary syndrome 578 
(PCOS) [women with PCOS and OSA (PCOS OSA); women with PCOS without OSA (PCOS No OSA)]. 579 
 580 
Figure 6. Effect of obstructive sleep apnoea (OSA) on measures of glucose metabolism and insulin 581 
resistance in women with polycystic ovary syndrome (PCOS) [fasting plasma glucose; 2-hour 582 
plasma glucose after a standard oral glucose tolerance test (OGTT); haemoglobin A1C (HbA1C); 583 
homeostasis model for insulin resistance (HOMA-IR); fasting insulin plasma levels; women with 584 
PCOS and OSA (PCOS OSA); women with PCOS without OSA (PCOS No OSA)]. 585 
 586 
Figure 7. Effect of obstructive sleep apnoea (OSA) on blood lipids in women with polycystic ovary 587 
syndrome (PCOS) [women with PCOS and OSA (PCOS OSA); women with PCOS without OSA (PCOS 588 
No OSA)]. 589 
 590 
Figure 8. Effect of obstructive sleep apnoea (OSA) on the incidence of metabolic syndrome in 591 
women with polycystic ovary syndrome (PCOS) [women with PCOS and OSA (PCOS OSA); women 592 
with PCOS without OSA (PCOS No OSA)]. 593 
The study by Nandalike et al. included adolescent girls with PCOS and the diagnosis of the metabolic 594 
syndrome was based on the Weiss criteria 
46
. The study by Chatterjee et al. included adult women 595 
with PCOS and the metabolic syndrome was diagnosed based on the National Cholesterol Education 596 
Programme, Adult Treatment Panel (NCEP ACT III) criteria 
47
.  597 
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Table 1. Characteristics of included studies [ordered alphabetically based on the first author’s surname].  
Study Country 
Study 
design 
Publicat
ion type 
Population N Ethnicity Age BMI 
PCOS 
diagnosis 
OSA diagnosis 
Age 
(per group) 
AHI 
(per group) 
       (yr) (Kg/m
2
) Criteria Method events/h 
PCOS 
OSA 
PCOS no 
OSA 
P-value 
PCOS 
OSA 
PCOS no 
OSA 
P-value 
Chatterjee 
et al. 2014 
23
 
India CS J. Article Adults 50 South Asian NR 28 ±3.0 Rotterdam PSG 
RDI ≥5 + 
symptoms 
or RDI >15 
NR NR  NR NR  
Kenigsberg 
et al. 2015 
22
 
USA CS 
C. 
Abstract 
Mixed 
(13-21 yr) 
31 NR 
16.7 
±2.4 
NR Rotterdam PSG AHI>2 NR NR  NR NR  
Nandalike 
et al. 2012 
21
 
USA CS J. Article Adolescents 28 
17.9% AA, 14.3% 
Hispanic, 14.3% 
White, 53.6% Mixed 
16.8 
±1.9 
44.8 
±8.8 
Rotterdam* PSG 
AHI > 5 or 
AI > 1 
16.8 
±2.1 
16.6 
±1.7 
0.8 NR NR  
Tasali et al. 
2008 
25
 
USA CS J. Article Adults 52 62% AA or Hispanic 
29.7 
±5.1 
39.2 
±7.2 
NIH PSG AHI > 5 
31.6 
±5.4 
27.3 
±3.4 
0.002 
19.4 
±10.8 
2.0  
±1.9 
< 0.0001 
Tock et al. 
2014 
28
 
Brazil CS J. Article 
Mixed  
(16-45 yr) 
38 NR 
28.3 
±6.8 
32.9 
±7.7 
Rotterdam PSG AHI ≥5 
28.3 
±5 
28.4 
±7.5 
0.968 
23.7  
±22.3 
1.3  
±1.5 
< 0.001 
Vgontzas et 
al. 2001 
24
 
USA CS J. Article 
Mixed 
 (16-45 yr) 
53 NR 
30.4 
±6.6 
38.7 
±8.0 
NIH PSG 
AHI ≥ 10 + 
symptoms 
34 
±8.4 
29.6 
±5.3 
NS NR NR  
Data presented as mean ± standard deviation. AA, African American; AHI, Apnoea hypopnoea index; AI, apnoea index; BMI, body mass index; C. Abstract, 
conference abstract; CS, cross-sectional study; h, hour; J. Article, journal article; N, sample size; NIH, National Institutes of Health; NR, not reported; NS, not 
significant; OSA, obstructive sleep apnoea; PCOS, polycystic ovary syndrome; PSG, Polysomnography; RDI, respiratory distress index; yr, years; *all 
participants also fulfilled the NIH criteria for PCOS diagnosis in addition to the 2003 Rotterdam criteria. All the studies were in women of reproductive 
age/pre-menopausal. 
  
Page 19 of 35 Sleep
20 
 
Table 2. The relationship between obstructive sleep apnoea (OSA) and total and free testosterone plasma levels in women with polycystic ovary 
syndrome (PCOS) [women with PCOS and OSA (PCOS OSA); women with PCOS without OSA (PCOS No OSA)].  
Study Number of Participants Total Testosterone Free Testosterone 
  PCOS OSA/PCOS no OSA PCOS OSA PCOS no OSA P-value PCOS OSA PCOS no OSA P-value 
Vgontzas et al. 
2001 
24
 
9/44 276.2 ±73.1 nmol/L 284.8 ±26.4 nmol/L NS 124.8 ±44.52 nmol/L 118.1 ±16.54 nmol/L NS 
Tasali et al. 2008 
25
 29/23 67.9  ±4.3 pg/ml 76.3 ±6.4 pg/ml 0.19 20.6 ±7 pg/ml 21.3 ±7.2 pg/ml 0.32 
Nandalike et al. 
2012 
21
 
16/12 54.2 ±30.1 ng/dL 51 ±23.3 ng/dL 0.2 9.7 ±4.2 pg/ml 7.6 ±4.5 pg/ml 0.3 
Tock et al. 2014 
28
 12/26 78.6 ±42.4 ng/dL 55.4 ±31.3 ng/dL 0.066 19 ±13 pg/ml 11 ±8 pg/ml 0.014 
Chatterjee et al. 
2014 
23
 
33/17 NA NA  3.43 ±3.78 ng/ml 2.01 ±2.47 ng/ml 0.167 
Data presented as mean ±standard deviation. NA, not available; NS, not significant. 
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13. Supplementary data 
This paper includes an online supplement: 
Table S1. Characteristics of excluded studies. 
Appendix 1. Search strategy. 
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Figure 2. Risk of bias of included studies.  
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Figure 3. Effect of obstructive sleep apnoea (OSA) on anthropometric measures in women with polycystic 
ovary syndrome (PCOS) [body mass index (BMI in kg/m2) for adult women with PCOS; BMI Z-score for the 
sub group of adolescent girls with obesity and PCOS; waist circumference; waist-to-hip ratio (WHR); women 
with PCOS and OSA (PCOS OSA); women with PCOS without OSA (PCOS No OSA)].  
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Figure 4. Effect of obstructive sleep apnoea (OSA) on systolic and diastolic blood pressure in women with 
polycystic ovary syndrome (PCOS) [women with PCOS and OSA (PCOS OSA); women with PCOS without 
OSA (PCOS No OSA)].  
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Figure 5. Effect of obstructive sleep apnoea (OSA) on hirsutism (based on the modified Ferriman-Gallwey 
score) and sex hormone binding globulin in women with polycystic ovary syndrome (PCOS) [women with 
PCOS and OSA (PCOS OSA); women with PCOS without OSA (PCOS No OSA)].  
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Figure 6. Effect of obstructive sleep apnoea (OSA) on measures of glucose metabolism and insulin resistance 
in women with polycystic ovary syndrome (PCOS) [fasting plasma glucose; 2-hour plasma glucose after a 
standard oral glucose tolerance test (OGTT); haemoglobin A1C (HbA1C); homeostasis model for insulin 
resistance (HOMA-IR); fasting insulin plasma levels; women with PCOS and OSA (PCOS OSA); women with 
PCOS without OSA (PCOS No OSA)].  
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Figure 7. Effect of obstructive sleep apnoea (OSA) on blood lipids in women with polycystic ovary syndrome 
(PCOS) [women with PCOS and OSA (PCOS OSA); women with PCOS without OSA (PCOS No OSA)].  
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Figure 8. Effect of obstructive sleep apnoea (OSA) on the incidence of metabolic syndrome in women with 
polycystic ovary syndrome (PCOS) [women with PCOS and OSA (PCOS OSA); women with PCOS without 
OSA (PCOS No OSA)].  The study by Nandalike et al. included adolescent girls with PCOS and the diagnosis 
of the metabolic syndrome was based on the Weiss criteria (ref 65). The study by Chatterjee et al. included 
adult women with PCOS and the metabolic syndrome was diagnosed based on the National Cholesterol 
Education Programme, Adult Treatment Panel (NCEP ACT III) criteria (ref 66).  
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Online data supplement 
Table S1. Characteristics of excluded studies [ordered by year of publication].  
Study Reason for exclusion 
Fogel et al. 2001 
1
 
No comparisons were made between women with polycystic ovary syndrome (PCOS) and obstructive sleep apnoea 
(OSA) and those with PCOS without OSA. 
Gopal et al. 2002 
2
 No comparisons were made between women with PCOS and OSA and those with PCOS without OSA 
Tasali et al. 2006 
3
 No information on how many women had OSA 
Vgontzas et al. 2006 
4
 Only participants without OSA were included 
Yang et al. 2009 
5
 None of the study participants had OSA 
De Sousa et al. 2010 
6
 None of the study participants had OSA - Duplicate publication to De Sousa 2012 
7
. 
De Sousa et al. 2010a 
8
 None of the study participants had OSA - Duplicate publication to De Sousa 2012 
7
.  
Yang et al. 2010 
9
 Duplicate publication to Yang 2009 
5
 
De Sousa et al. 2011 
10
 None of the study participants had OSA - Duplicate publication to De Sousa 2012 
7
.  
De Sousa et al. 2011a 
11
 None of the study participants had OSA - Duplicate publication to De Sousa 2012 
7
.  
Nandalike et al. 2011  
12
 No sleep studies performed for OSA diagnosis 
Tasali et al. 2011 
13
 Only women with OSA were included 
De Sousa et al. 2012 
7
 None of the study participants had OSA 
De Sousa et al. 2012a 
14
 None of the study participants had OSA - Duplicate publication to De Sousa 2012 
7
.  
Mokhlesi et al. 2012 
15
 No sleep studies performed for OSA diagnosis 
AbdelWahab et al. 2013 
16
 No comparisons were made between women with PCOS and OSA and those with PCOS without OSA. 
Gateva et al. 2013 
17
 Only two patients had OSA. No data comparing women with PCOS and OSA to women with PCOS without OSA 
Morselli et al. 2013 
18
 No comparisons were made between women with PCOS and OSA and those with PCOS without OSA 
Temple et al. 2013 
19
 No comparisons were made between women with PCOS and OSA and those with PCOS without OSA 
Temple et al. 2013a 
20
 No comparisons were made between women with PCOS and OSA and those with PCOS without OSA 
Zea-Hernandez et al. 2014 
21
 No comparisons were made between women with PCOS and OSA and those with PCOS without OSA 
Suri et al. 2016 
22
 Duplicate publication to Chatterjee 2014 
23
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Appendix 1. Search strategy 
The initial search was performed on 11
th
 of April 2016 and a second search was performed on 7
th
 of 
February 2017. In addition to the electronic databases below we manually searched the references 
of all relevant papers and review articles. 
- Medline (Ebsco) 
# Query Limiters/Expanders 
S1 MH "Polycystic Ovary Syndrome" Search modes - Boolean/Phrase 
S2 (polycystic N3 ovar*) or PCOS or "stein leventhal" or 
(sclerocystic N3 ovar*) or "hyperandrogenic anovulation" 
Search modes - Boolean/Phrase 
S3 (MH "Sleep Apnea Syndromes+") Search modes - Boolean/Phrase 
S4 (sleep* N3 (apnea* or apnoea* or respirat* or breath*)) 
or OSA or SHS or OSAHS or SAHS or hypopnea* or 
hypopnoea* 
Search modes - Boolean/Phrase 
S5 ( S1 OR S2 ) AND ( S3 OR S4 ) Search modes - Boolean/Phrase 
 
- Embase (Ovid) 
# Search Terms 
1 exp ovary polycystic disease 
2 ((polycystic adj3 ovar*) or PCOS or "stein leventhal" or (sclerocystic adj3 ovar*) or 
"hyperandrogenic anovulation").mp. [mp=title, abstract, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
3 exp sleep disordered breathing 
4 ((sleep* adj3 (apnea* or apnoea* or respirat* or breath*)) or OSA or SHS or OSAHS or SAHS or 
hypopnea* or hypopnoea*).mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] 
5 1 or 2 
6 3 or 4 
7 5 and 6 
 
- CINAHL  (Ebsco) 
# Search Terms Search Options 
S1 (MH "Polycystic Ovary Syndrome")  Search modes - Boolean/Phrase 
S2 (polycystic N3 ovar*) or PCOS or "stein leventhal" or 
(sclerocystic N3 ovar*) or "hyperandrogenic anovulation"  
Search modes - Boolean/Phrase 
S3 (MH "Sleep Apnea Syndromes+")  Search modes - Boolean/Phrase 
S4 (sleep* N3 (apnea* or apnoea* or respirat* or breath*)) or 
OSA or SHS or OSAHS or SAHS or hypopnea* or 
hypopnoea*  
Search modes - Boolean/Phrase 
S5 S1 OR S2  Search modes - Boolean/Phrase 
S6 S3 OR S4  Search modes - Boolean/Phrase 
S7 S5 AND S6  Search modes - Boolean/Phrase 
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- Opengrey (http://www.opengrey.eu/) 
 ((polycystic NEAR/3 ovar*) OR PCOS OR "stein leventhal" OR (sclerocystic NEAR/3 ovar*) OR 
"hyperandrogenic anovulation") AND ((sleep NEAR/3 (apnea* or apnoea* or respirat* or breath*)) 
OR OSA OR SHS OR OSAHS OR SAHS OR hypopnea* or hypopnoea*). 
- Web of Science 
# Search Term 
#1 
TOPIC: ("polycystic ovary syndrome" or "ovary polycystic disease*" or pcos or "stein 
leventhal" or "hyperandrogenic anovulation") OR TOPIC: (polycystic near/3 ovar*) OR TOPIC: 
(sclerocystic near/3 ovar*) 
DocType=All document types; Language=All languages;  
#2 
TOPIC: ("sleep apnea syndrome" or "sleep disordered breathing") OR TOPIC: (sleep near/3 
(apnea or apnoea or respirat* or breath*)) OR TOPIC: (osa or shs or osahs or sahs or 
hypopnea* or hypopnoea*) 
DocType=All document types; Language=All languages;  
#3 
#2 AND #1  
DocType=All document types; Language=All languages;  
 
- Scopus 
( TITLE-ABS-KEY ( sclerocystic  W/3  ovar* )  OR  TITLE-ABS-KEY ( polycystic  W/3  ovar* )  OR  TITLE-
ABS-KEY ( "polycystic ovary syndrome"  OR  "ovary polycystic disease*"  OR  pcos  OR  "stein 
leventhal"  OR  "hyperandrogenic anovulation" ) )  AND  ( ( TITLE-ABS-KEY ( "sleep apnea syndrome"  
OR  "sleep disordered breathing" )  OR  TITLE-ABS-KEY ( sleep  W/3  ( apnea  OR  apnoea  OR  
respirat*  OR  breath* ) )  OR  TITLE-ABS-KEY ( osa  OR  shs  OR  osahs  OR  sahs  OR  hypopnea*  OR  
hypopnoea* ) ) ) 
 
- PsycInfo (ProQuest) 
(SU.EXACT.EXPLODE("Sleep Apnea") OR ((sleep* N/3 (apnea* or apnoea* or respirat* or breath*)) or 
OSA or SHS or OSAHS or SAHS or hypopnea* or hypopnoea*)) AND ((polycystic N/3 ovar*) or PCOS 
or "stein leventhal" or (sclerocystic N/3 ovar*) or "hyperandrogenic anovulation"). 
 
- Endocrine abstracts (http://www.endocrine-abstracts.org/) 
Search terms Advanced search options 
Polycystic ovaries and sleep apnea Boolean 
Search for grammatical variations 
Similarity to search phrase: Generous differences 
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- American Endocrine Society meeting abstracts (http://press.endocrine.org/series/endo-
meetings) 
Search terms: Polycystic ovary and sleep apnea 
Search filters: Meeting Abstracts. 
 
- American Thoracic Society meeting abstracts 
(http://www.atsjournals.org/search/advanced) 
Search Terms: PCOS or polycystic. 
- Sleep (the joint meeting of the American Academy of Sleep Medicine and the Sleep 
Research Society) (http://www.sleepmeeting.org/abstract-supplements) 
 
Search terms: PCOS or polycystic. 
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